CYTRX CORP (CYTR) Upgraded by Zacks to OUTPERFORM

Zacks Zacks Investment Research upgraded shares of CYTRX CORP (CYTR) from NEUTRAL to OUTPERFORM on November 20, 2012, with a target price of $2.00.

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on CYTRX CORP (CYTR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply